Fischer Nina, Tarpataki Noémi, Leidi Federica, Rostaher Ana, Favrot Claude
Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057, Zurich, Switzerland.
Department and Clinic of Internal Medicine, University of Veterinary Medicine, István utca 2, Budapest, 1078, Hungary.
Vet Dermatol. 2018 Jun 17. doi: 10.1111/vde.12657.
Previously published studies evaluating a recombinant Der f 2-based immunotherapy have demonstrated efficacy in the treatment of dogs experimentally and naturally sensitized to house dust mites (HDM). Der f 2 sensitization is thought to play a minor role in European atopic dogs sensitized to HDM.
The study evaluated the short-term efficacy of a recombinant Der f 2 product in the treatment of naturally sensitized atopic dogs in Switzerland and Hungary.
Fifteen atopic dogs with positive test reactions to Dermatophagoides farinae (Df).
Recombinant Der f 2 allergens were injected subcutaneously at increasing doses once weekly for 6 weeks. Canine Atopic Dermatitis Extent and Severity Index (CADESI-04), pruritus Visual Analog Scale (pVAS) and medication scores were assessed at days 0 and 42. Efficacy was recorded as excellent, good, fair or poor, depending on the number of scores decreasing by more than 50%.
Mean CADESI, pVAS and medication scores at inclusion were 35, 6 and 15 (SD = 30, 2, 7), respectively. At Day 42 the scores decreased to 8, 3 and 5, respectively (Wilcoxon matched pairs signed rank tests P = 0.0002, 0.002 and 0.001). Four dogs were classified as excellent responders with a reduction of >50% in all three scores. Nine dogs were classified as good (five) or fair (four) responders and scores deteriorated in two dogs.
These data suggest that recombinant Der f2 allergens may be as effective and show benefit faster than traditional allergen immunotherapy in European dogs sensitized to Df.
先前发表的评估基于重组Der f 2的免疫疗法的研究已证明，该疗法在治疗实验性和自然致敏于屋尘螨（HDM）的犬类中具有疗效。Der f 2致敏被认为在欧洲对HDM致敏的特应性犬中起次要作用。
本研究评估了重组Der f 2产品在治疗瑞士和匈牙利自然致敏的特应性犬中的短期疗效。
15只对粉尘螨（Df）试验反应呈阳性的特应性犬。
每周一次皮下注射递增剂量的重组Der f 2变应原，持续6周。在第0天和第42天评估犬特应性皮炎范围和严重程度指数（CADESI - 04）、瘙痒视觉模拟量表（pVAS）和用药评分。根据评分下降超过50%的数量，将疗效记录为优、良、中或差。
纳入时的平均CADESI、pVAS和用药评分分别为35、6和15（标准差 = 30、2、7）。在第42天，评分分别降至8、3和5（Wilcoxon配对符号秩检验P = 0.0002、0.002和0.001）。4只犬被分类为优秀反应者，所有三项评分均降低>50%。9只犬被分类为良好（5只）或中等（4只）反应者，2只犬的评分恶化。
这些数据表明，重组Der f2变应原在对Df致敏的欧洲犬中可能与传统变应原免疫疗法一样有效，且起效更快。
